• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

    2/15/23 8:00:00 AM ET
    $AGRX
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AGRX alert in real time by email

    Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team

    GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

    Appointment of Ernie De Paloantonio to Chief Financial Officer Further Strengthens CPSI's Leadership Team

    Ernie brings over 30 years of financial and business experience in the pharmaceutical industry including both private and public commercial and manufacturing companies. Most recently, he was Chief Financial Officer of Journey Medical Corporation, a commercial stage dermatology company. Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.

    As CFO, Ernie will have responsibility for both finance and information technology.

    "I am pleased to be able to work with Ernie again as we look to grow this promising specialty development and manufacturing business. Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions. He will play an instrumental role working closely with myself, members of the leadership team, and our investors on our long-term growth strategy and its execution," said Mark Sirgo, CEO of CPSI, in making the announcement.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug and consumer product delivery technologies. With a track record spanning nearly 30 years, the company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by B-FLEXION and Webster Equity Partners. Prior to the CPSI transaction with Webster Equity Partners in October 2022, Gurnet Point Capital, an affiliate of B-Flexion, led the original investment in Corium Pharma Solutions through a take-private transaction in October 2018.

    About Gurnet Point Capital & B-FLEXION

    Gurnet Point Capital, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    B-FLEXION is a private, entrepreneurial investment firm, partnering with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. The company oversees growth-oriented operating businesses and asset managers, always with an 'active owner' philosophy. B-FLEXION invests across a wide range of industries, including healthcare. Gurnet Point Capital, an affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences investment strategy.

    https://www.bflexion.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    Contact

    Gartman PR

    (202) 413-4226

    Cision View original content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html

    SOURCE Corium Pharma Solutions Inc.

    Get the next $AGRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    7/25/2025$170.00Overweight → Neutral
    Analyst
    Procter & Gamble Company
    $PG
    7/14/2025$170.00Outperform → In-line
    Evercore ISI
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    Procter & Gamble Company
    $PG
    11/25/2024$160.00 → $209.00Neutral → Buy
    DA Davidson
    Procter & Gamble Company
    $PG
    10/10/2024$159.00Neutral
    DA Davidson
    Procter & Gamble Company
    $PG
    9/30/2024$163.00Overweight → Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    9/24/2024$174.00Neutral
    Piper Sandler
    More analyst ratings

    $AGRX
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iconic Laundry Care Brand, Bounce, Unveils New Bounce Intense Dryer Sheets With Freshness That Lasts For Up To Four Weeks

    NEW Bounce Intense infuses clothes with long-lasting freshness, leveraging innovative heat-activated technology that bursts with movement Bounce, the leading dryer sheet brand from Procter & Gamble, is resetting laundry expectations with the introduction of Bounce Intense, a multi-benefit dryer sheet engineered to deliver 10x the freshness of a leading base dryer sheet*. Launched in September 2025, Bounce Intense not only offers the static and wrinkle control that is a hallmark of the brand, but also provides the ultimate fresh experience that bursts from the dryer and lasts through wear for up to four weeks. This press release features multimedia. View the full release here: https://www

    9/29/25 9:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G to Webcast Discussion of First Quarter 25/26 Earnings Results on October 24

    The Procter & Gamble Company (NYSE: PG) will webcast a discussion of its first quarter earnings results on Friday, October 24, 2025, beginning at 8:30 a.m. ET. Media and investors may access the live audio webcast at www.pginvestor.com. The webcast will also be available for replay. About Procter & Gamble P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately

    9/26/25 12:00:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    All Roads Lead to Oz: Olay Body and Secret Unveil Limited-Edition Wicked: For Good Collection

    Olay Body and Secret join forces with Universal Pictures for new line-up of body washes and deodorants inspired by the epic conclusion to the global cinematic Wicked sensation Universal Pictures' Wicked: For Good Arrives in Theaters November 21, 2025. Olay Body and Secret are transforming your body care routine from mundane to magical with the new Wicked: For Good collection, available for a limited-time only. Inspired by the captivating worlds of the witches of Oz, Elphaba and Glinda, this hydrating collection features serum-infused body washes and clinical strength deodorants formulated with superior skincare technology and enchanting scents. The collection is available for purchase t

    9/25/25 10:53:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    SEC Filings

    View All

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/25/25 12:17:03 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/25/25 12:14:17 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 11-K filed by Procter & Gamble Company

    11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

    9/24/25 1:05:28 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Human Resources Officer Purushothaman Balaji

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:35:48 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Chief Operating Officer Jejurikar Shailesh

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:34:33 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 4 filed by Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier

    4 - PROCTER & GAMBLE Co (0000080424) (Issuer)

    9/17/25 9:32:43 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Procter & Gamble downgraded by Analyst with a new price target

    Analyst downgraded Procter & Gamble from Overweight to Neutral and set a new price target of $170.00

    7/25/25 9:00:02 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Procter & Gamble from Outperform to In-line and set a new price target of $170.00

    7/14/25 8:41:25 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Procter & Gamble downgraded by Redburn Atlantic with a new price target

    Redburn Atlantic downgraded Procter & Gamble from Buy to Neutral and set a new price target of $161.00

    5/1/25 7:44:23 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Leadership Updates

    Live Leadership Updates

    View All

    IFF Appoints Virginia "Gina" Drosos to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

    6/9/25 5:46:00 PM ET
    $IFF
    $PG
    $SIG
    Major Chemicals
    Industrials
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Appoints Craig Arnold to Board of Directors

    The Procter & Gamble Company (NYSE:PG) today announced the appointment of Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, to its Board of Directors, effective June 9, 2025. Mr. Arnold brings significant experience as a successful chief executive of a global enterprise serving businesses and customers in more than 175 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609584955/en/P&G Appoints Craig Arnold to Board of Directors With a distinguished career at Eaton, a global leader in power infrastructure and technology, Arnold led the company through transformative changes from 2016 to Ma

    6/9/25 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Tide Teams Up with Marvel Studios to Highlight Stain Stories and Host Exclusive, First-Ever "Collateral Stains Screening" Experience for Marvel Studios' Captain America: Brave New World

    Tide Launches Most Powerful Clean and Best Stain Removal POD – in any Universe: Ultra Oxi Boost Power PODS Throughout the Marvel Cinematic Universe (MCU), collateral stains are a way of life. And, in the highly anticipated Marvel Studios' "Captain America: Brave New World," in theaters February 14, everyday people in the MCU sometimes have to face clouds of dirt, spilled coffee and guacamole stains that occur by virtue of being courtside to action-packed superhero moments. That's why Tide®, America's #1 trusted laundry detergent*, has joined forces with the film to show how the biggest stains in the universe demand the most powerful clean – in any universe. This press release features mu

    1/8/25 10:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    $AGRX
    $PG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/22/24 4:50:46 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/9/24 2:20:54 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Agile Therapeutics Inc.

    SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

    7/2/24 3:44:23 PM ET
    $AGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $PG
    Financials

    Live finance-specific insights

    View All

    P&G Announces Fourth Quarter and Fiscal Year 2025 Results

    Q4 '25: Net Sales +2%; Organic Sales +2%; Diluted EPS +17%; Core EPS +6% FY '25: Net Sales 0%; Organic Sales +2%; Diluted EPS +8%; Core EPS +4% The Procter & Gamble Company (NYSE:PG) reported fourth quarter and fiscal year 2025 results. "We grew sales and profit in fiscal 2025 and returned high levels of cash to shareowners in a dynamic, difficult and volatile environment," said Jon Moeller, Chairman of the Board, President and Chief Executive Officer. "We've put in place strong plans to continue to deliver for all stakeholders in the current environment. In fiscal 2026, we expect to deliver another year of organic sales growth, Core EPS growth and strong adjusted free cash flow produ

    7/29/25 7:00:00 AM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    Shailesh Jejurikar Elected P&G President and Chief Executive Officer

    Jon Moeller to Become Executive Chairman The Procter & Gamble Company (NYSE:PG) announced today that Shailesh Jejurikar, currently Chief Operating Officer, will succeed Jon Moeller as Procter & Gamble's President and Chief Executive Officer, effective January 1, 2026. The Board has also nominated Mr. Jejurikar to stand for election as a Director at the annual shareholder meeting in October 2025. On January 1, 2026, Jon Moeller will become Procter & Gamble's Executive Chairman. In this role, Mr. Moeller will lead the Board of Directors and provide advice and counsel to the CEO on Company matters. This press release features multimedia. View the full release here: https://www.businesswire.

    7/28/25 5:00:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary

    P&G Declares Quarterly Dividend for July 2025

    The Board of Directors of The Procter & Gamble Company (NYSE:PG) declared a quarterly dividend of $1.0568 per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after August 15, 2025 to Common Stock shareowners of record at the close of business on July 18, 2025, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareowners of record at the start of business on July 18, 2025. P&G has been paying a dividend for 135 consecutive years since its incorporation in 1890 and has increased its dividend for 69 consecutive years. This reinforces our commitment to return cash to shareowners, many of who

    7/8/25 4:15:00 PM ET
    $PG
    Package Goods/Cosmetics
    Consumer Discretionary